Details of the Drug

General Information of Drug (ID: DMN8HRU)

Drug Name

Methoxyphenamine

Synonyms

Euspirol; METHOXYPHENAMINE; Methamphetamine, 2-methoxy; Methoxifenaminio; Methoxiphenadrin; Methoxiphenadrinum; Methoxyphenadrine; Methoxyphenamin; Methoxyphenamine [INN:BAN]; Methoxyphenaminum; Methoxyphenaminum [INN-Latin]; Metossifenamina [DCIT]; Metoxifenaminio [INN-Spanish]; Orthoxine; Ortodrinex; Ortoxine; Oxalacetic acid orthoxine; Proasma; 2-Methoxy-N,alpha-dimethylphenethylamin; 2-Methoxy-N-methylamphetamine; 2-Methoxymethamphetamine; 93-30-1; Asmi; EINECS 202-237-7; o-Methoxy-N,alpha-dimethylphenethylamine

Indication

Disease Entry	ICD 11	Status	REF
Chronic obstructive pulmonary disease	CA22	Investigative	[1]

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

179.26

Topological Polar Surface Area (xlogp)

2.6

Rotatable Bond Count (rotbonds)

4

Hydrogen Bond Donor Count (hbonddonor)

1

Hydrogen Bond Acceptor Count (hbondacc)

2

Chemical Identifiers

Formula: C11H17NO
IUPAC Name: 1-(2-methoxyphenyl)-N-methylpropan-2-amine
Canonical SMILES: CC(CC1=CC=CC=C1OC)NC
InChI: OEHAYUOVELTAPG-UHFFFAOYSA-N
InChIKey: 1S/C11H17NO/c1-9(12-2)8-10-6-4-5-7-11(10)13-3/h4-7,9,12H,8H2,1-3H3

Cross-matching ID

PubChem CID: 4117
ChEBI ID: CHEBI:134817
CAS Number: 93-30-1
DrugBank ID: DB13624
INTEDE ID: DR1049

Molecular Interaction Atlas of This Drug

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2D6 (CYP2D6)_{Main DME}	DECB0K3	CP2D6_HUMAN	Substrate	[2]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

References

1	Index Nominum 2000: International Drug Directory. Page: 670.
2	Metabolism of methoxyphenamine and 2-methoxyamphetamine in P4502D6-transfected cells and cell preparations. Xenobiotica. 1995 Sep;25(9):895-906.
3	Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
4	Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
5	CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
6	Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
7	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
8	Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
9	Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
10	Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
11	Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
12	Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.